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Abstract 
Genetic variations within cytochrome P450 2B6 (CYP2B6) contribute to inter-
individual variation in the metabolism of clinically important drugs, including 
cyclophosphamide, bupropion, methadone and efavirenz (EFZ). In this study, we 
performed an in vitro analysis of 40 CYP2B6 allelic variant proteins including seven 
novel variants identified in 1070 Japanese individuals. Wild-type and 39 variant proteins 
were heterologously expressed in 293FT cells to estimate the kinetic parameters (Km, Vmax, 
and CLint) of EFZ 8-hydroxylation and 7-ethoxy-4-trifluoromethylcoumarin (7-ETC) O-
deethylation activities. The concentrations of CYP2B6 variant holo-enzymes were 
measured by using carbon monoxide (CO)-reduced difference spectroscopy, and the wild-
type and 28 variants showed a peak at 450 nm. The kinetic parameters were measured for 
the wild-type and 24 variant proteins. The values for the remaining 15 variants could not 
be determined because the enzymatic activity was not detected at the highest substrate 
concentration used. Compared to wild-type, six variants showed significantly decreased 
EFZ 8-hydroxylation CLint values, while these values were significantly increased in 
another six variants, including CYP2B6.6. Although 7-ETC O-deethylation CLint values 
of CYP2B6 variants did not differ significantly from that of CYP2B6.1, the CLint ratios 
obtained for 7-ETC O-deethylation were highly correlated with EFZ 8-hydroxylation. 
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Furthermore, three-dimensional structural modeling analysis was performed to elucidate 
the mechanism of changes in the kinetics of CYP2B6 variants. Our findings could provide 
evidence of the specific metabolic activities of the CYP2B6 proteins encoded by these 
variant alleles. 
 
Keywords: Cytochrome P450; CYP2B6; Genetic polymorphisms; Efavirenz; 
Pharmacogenetics; Drug metabolism 
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1. Introduction 
The Cytochrome P450 2B6 enzyme (CYP2B6) plays a major role in the 
biotransformation of several therapeutically important drugs, including 
cyclophosphamide, bupropion, methadone, and efavirenz (EFZ) [1]. The contribution of 
CYP2B6 to drug metabolism is relatively small, accounting for approximately 7% [2]. 
However, the inter-individual variability in CYP2B6 activity influences drug 
responsiveness, efficacy, and the occurrence of adverse effects. The observed impact of 
CYP2B6 on drug metabolism lies in the extensively polymorphic nature of the CYP2B6 
gene, with numerous variants in coding and non-coding regions, believed to be 
responsible for the observed inter-individual and inter-ethnic differences in drug response 
[3]. A large number of CYP2B6 genetic polymorphisms have been identified to date, and 
the Pharmacogene Variation Consortium website 
(https://www.pharmvar.org/gene/CYP2B6) currently lists 38 distinct star-alleles (last 
accessed: July 1st, 2018). Thus far, many studies have reported the pharmacogenetic 
impacts of CYP2B6 in vivo and in vitro. However, the continual discovery of new variants 
means that in-depth studies of their effects on drug metabolism have become 
indispensable in the clinical setting. 
CYP2B6 genetic polymorphisms are associated with drug plasma concentrations 
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and with treatment efficacy, continuation, adverse reactions, relapse, and survival rates. 
CYP2B6*6 (516G>T and 785A>G), which results in two amino acid changes, Gln172His 
and Lys262Arg, is the most common variant allele in various populations, including 
Asians and Caucasians [3]. The CYP2B6*5 allele (1459C>T, Arg487Cys) occurs 
predominantly in 9–12% of Caucasians [4]. Homozygous CYP2B6*6 correlates with high 
plasma EFZ levels in human immunodeficiency virus (HIV)-1 patients, an increased risk 
of central nervous system side effects, and with EFZ treatment discontinuation [5–7]. 
Additionally, homozygous CYP2B6*6 allele patients with heroin addiction who also 
exhibit poor methadone metabolism have also shown disparities in the dose required for 
effective treatment of methadone [8]. Furthermore, patients with the CYP2B6*1/*5 
genotype that undergo autologous hematopoietic cell transplantation, an important 
procedure for lymphoma treatment after cyclophosphamide-containing conditioning, 
have a higher two-year relapse rate and overall decreased survival rate than patients with 
the wild-type allele [9]. Thus, it has become necessary to consider CYP2B6 genetic 
polymorphisms for successful clinical practice. 
Characterization of the functional effect of variant alleles on CYP2B6 activity 
has involved the use of various in vitro heterologous expression systems over the years. 
Using COS-1 mammalian cells, Jinno et al. have expressed six variants (CYP2B6.2–
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CYP2B6.7) and examined their enzymatic properties using 7-ethoxy-4-
trifluorometylcoumarin (7-ETC) O-deethylation [10]. Additionally, using bupropion and 
EFZ, Radloff et al. analyzed 10 variants (CYP2B6.5, CYP2B6.6, and eight amino acid-
substituted enzymes expressed in COS-1 cells [11]. Furthermore, using COS-7 cells, we 
have previously performed a comprehensive analysis of 26 allelic variants by determining 
the kinetic parameters of 7-ETC O-deethylation, selegiline N-demethylation/N-
depropagylation, and artemether demethylation [12, 13]. However, the effects of CYP2B6 
genetic polymorphisms on drug metabolism remains poorly understood, and has not been 
sufficiently applied in clinical practice. Recently, the Tohoku Medical Megabank 
Organization (ToMMo) has reported the whole-genome sequences (WGS) of 1070 
healthy Japanese individuals and has constructed a Japanese population reference panel 
(1KJPN) [14]. Seven novel CYP2B6 single nucleotide variants (SNVs), with unknown 
functional alterations, were identified in these individuals (Fig. 1). 
To develop the most suitable pharmacotherapy for CYP2B6-metabolized drugs, 
further investigation is required to understand the differences in allele-specific CYP2B6 
variant activity. In this study, we performed an in vitro analysis of 39 CYP2B6 allelic 
variants with amino acid substitutions (CYP2B6*2–CYP2B6*21, CYP2B6*23–
CYP2B6*28, CYP2B6*31–CYP2B6*35, CYP2B6*37, and seven novel CYP2B6 variants) 
8 
 
(Table 1). The wild-type CYP2B6.1 protein and all 39 variants were heterologously 
expressed in 293FT cells under the same conditions, and their kinetic parameters—the 
Michaelis constant (Km), maximum velocity (Vmax), and intrinsic clearance (CLint = 
Vmax/Km)—for EFZ 8-hydroxylation were determined. We further measured the kinetic 
parameters of 7-ETC O-deethylation in order to confirm the substrate specificity among 
CYP2B6 variants. EFZ, commonly used as an anti-HIV agent, is mainly metabolized by 
CYP2B6 [15, 16], and 7-ETC is a specific substrate for CYP2B6 [17]. We assessed the 
enzymatic activity of CYP2B6 holo-protein and performed a three-dimensional (3D) 
structural modeling analysis to elucidate the mechanism underlying the observed changes 
in the kinetics of CYP2B6 variants. The approach was then adopted to elucidate which 
CYP2B6 amino acid alterations affect the function of the protein. We believe this 
comprehensive CYP2B6 genetic polymorphism research will further clarify the genotype-
phenotype association intended for the clinical application of precision medicine. 
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2. Materials and methods 
2.1. Chemicals 
The following reagents were purchased from the listed sources: EFZ, from 
Tokyo Kasei Industry (Tokyo, Japan); 8-hydroxyefavirenz (8-HEZ) and 8-
hydroxyefavirenz-d4 (8-HEZ-d4), from Toronto Research Chemicals (Ontario, Canada); 
7-ETC, 7-hydroxy-4-trifluoromethylcoumarin (7-HTC), and dimanganese decacarbonyl 
(DMDC), from Sigma-Aldrich (Steinheim, Germany); oxidized β-nicotinamide-adenine 
dinucleotide phosphate oxidized form (NADP+), glucose-6-phosphate (G-6-P), and 
glucose-6-phosphate dehydrogenase (G-6-PDH), from Oriental Yeast (Tokyo, Japan); 
Sodium hydrosulfite (Na2S2O4), from Nacalai Tesque, (Kyoto, Japan); polyclonal anti-
human CYP2B6 antibody, from Abcam (Cambridge, MA, USA); polyclonal anti-
calnexin antibody, from Enzo Life Sciences (Farmingdale, NY, USA); and horseradish 
peroxidase (HRP)-conjugated goat anti-rabbit IgG, from Santa Cruz Biotechnology 
(Santa Cruz, CA, USA). All other chemicals and reagents were of the highest 
commercially available quality. 
 
2.2. CYP2B6 Sanger sequencing analysis 
To confirm the CYP2B6 sequence alterations identified by WGS, we performed 
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Sanger sequencing according to previously described methods [18]. PCR amplification 
was conducted using peripheral blood leukocyte genomic DNA isolated from whole 
blood by using the Gentra Puregene Blood Kit (Qiagen, Hilden, Germany) according to 
previously described methods [14]. Whole blood samples were obtained from Japanese 
subjects participating in the community-based cohort study conducted by ToMMo. 
Primer pairs were used to amplify sequences containing each CYP2B6 SNVs (Table 2). 
This study was conducted in accordance with the Declaration of Helsinki and all 
participants provided written informed consent according to the protocols approved by 
the Tohoku University Graduate School of Pharmaceutical Sciences committee 
(permission number 14-08), and the Tohoku Medical Megabank Organization committee 
(permission number 2017-4-26, 2017-4-58, and 2017-4-090). 
 
2.3. CYP2B6 cDNA cloning and construction of expression vectors 
CYP2B6 complementary DNA (cDNA) fragments, obtained from a human liver 
cDNA library, (TaKaRa, Shiga, Japan) were amplified by PCR using a forward primer 
(5′-CACCATGGAACTCAGCGTCCTCCTC-3′) and reverse primer (5′-
TCAGCGGGGCAGGAAGC-3′) with PfuUltra High-Fidelity DNA Polymerase (Agilent 
Technologies, Santa Clara, CA, USA). The underlined sequences in the forward primer 
11 
 
were introduced for directional TOPO cloning. The amplified fragments were subcloned 
into the pENTR/D-TOPO vector (Thermo Fisher Scientific, Waltham, MA, USA). 
Plasmids carrying CYP2B6*1 (wild-type) cDNA were used as a template to generate 29 
CYP2B6 constructs (CYP2B6*2–*5, *8, *9, *11, *12, *14, *15, *17, *18, *21, *23–*25, 
*27, *28, *31–*33, *35, and the seven novel variants) using a QuikChange Lightning 
Site-Directed Mutagenesis Kit (Agilent Technologies) according to the manufacturer’s 
instructions. Ten CYP2B6 constructs were generated from plasmids carrying other cDNA 
templates: CYP2B6*10 from CYP2B6*2 cDNA; CYP2B6*6 and CYP2B6*16 from 
CYP2B6*4 cDNA; and CYP2B6*7, *13, *19, *20, *26, *34, and *37 from CYP2B6*6 
cDNA. All prepared wild-type and variant cDNAs were confirmed by Sanger sequencing. 
The wild-type and variant CYP2B6 cDNA sequences were then subsequently subcloned 
into the pcDNA3.4 mammalian expression vector (Thermo Fisher Scientific). 
 
2.4. Expression of CYP2B6 variants in 293FT cells 
293FT cells (Thermo Fisher Scientific) were cultured in Dulbecco’s modified 
Eagle medium (Nacalai Tesque) containing 10% fetal bovine serum at 37ºC and 5% CO2. 
Cells were plated at a density of 2.0 × 106 cells/100-mm dish. Twenty-four hours after 
plating, the cells were transfected with a plasmid (5 μg) encoding CYP2B6 cDNA using 
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the TransFectin lipid reagent (Bio-Rad Laboratories, Hercules, CA, USA) according to 
the manufacturer’s instructions. After incubation for 24 h at 37°C, the cells were scraped 
off, and microsomal fractions were prepared as previously described [12]. The protein 
concentration was determined using a bicinchoninic acid protein assay Kit (Thermo 
Fisher Scientific). 
 
2.5. Western blotting analysis 
 Western blotting was performed according to standard procedures by using 10% 
sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE), with 5 μg of 
microsomal protein loaded per lane. CYP2B6 was detected using a polyclonal anti-human 
CYP2B6 antibody (1:1000) and HRP-conjugated goat anti-rabbit IgG (1:2500). The 
loading control used was calnexin, which was detected using a polyclonal anti-calnexin 
antibody (1:5000) and HRP-conjugated goat anti-rabbit IgG (1:10,000). The 
immunoblots were visualized using the SuperSignal™ West Dura extended duration 
substrate (Thermo Fisher Scientific). Chemiluminescence was quantified using a 
ChemiDoc XRS+ with Image Lab software (Bio-Rad Laboratories). 
 
2.6. Determination of microsomal P450 contents 
13 
 
CYP2B6 variant holo-enzymes were measured according to previously reported 
methods [19, 20], with several modifications. The microsomal fraction (0.80 ± 0.20 mg 
of microsomal proteins) was diluted to a final volume of 200 μL using 100 mM potassium 
phosphate buffer (pH 7.4) containing 20% glycerol (v/v). Protein samples (100 μL) were 
added to sample and reference cuvettes. A baseline between 400 and 500 nm was recorded 
using a Cary 300 UV-Vis spectrophotometer (Agilent Technologies). The sample cuvette 
was illuminated with over 20,000 lux LED-light for 30 s following the addition of 0.2 
mM DMDC [21]. Samples were reduced by freshly prepared 500 mM Na2S2O4 solution 
in both cuvettes. The carbon monoxide (CO)-difference spectra of both cuvettes, 
normalized to the baseline spectrum, were then recorded between 400 and 500 nm using 
a spectrophotometer. The spectra for each CYP2B6 variant were recorded in triplicate. 
Data analysis was conducted using a Jasco Spectra Manager (JASCO Corporation, Sendai, 
Japan). The CYP concentration was calculated using the maximum absorbance of the 
three recorded values normalized to the baseline spectrum because the spectrum baseline 
showed a difference in absorbance between 400 and 500 nm. Cuvettes (Sub-Micro Cells, 
16.50-Q-10/Z20) were purchased from Starna Scientific, Ltd. (London, UK). 
 
2.7. EFZ 8-hydroxylation assay 
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CYP2B6-mediated EFZ 8-hydroxylation was measured as previously described 
[15, 16], with several modifications. The incubation mixture consisted of the microsomal 
fraction (30 μg), EFZ (1, 2, 3, 5, 7.5, 10, 15, or 20 μM), 3.3 mM MgCl2, and 100 mM 
potassium phosphate buffer (pH 7.4) in a total volume of 150 μL. Following pre-
incubation at 37ºC for 5 min, reactions were initiated by the addition of NADPH-
generating medium. The mixture was incubated at 37ºC for 30 min. Reactions were 
terminated by adding 150 μL of acetonitrile containing 2 μM of 8-HEZ-d4 (internal 
standard). EFZ 8-hydroxylation assessment, using 20 μM of EFZ and 30 μg of the 
microsomal fraction containing wild-type and variant CYP2B6, showed that 8-HEZ 
formation was linear for incubations of up to 30 min. Moreover, when the reaction 
containing 20 μM of EFZ was incubated for 30 min, 8-HEZ formation was linear in the 
presence of up to 30 μg of microsomal protein (data not shown). 
After protein removal by centrifugation at 14,000 g for 5 min, 10 μL of the 
supernatant was injected into a liquid chromatography-tandem mass spectrometry (LC-
MS/MS) system. 8-HEZ was measured using the LC-MS/MS system in the negative ion 
detection mode at the electrospray ionization interface (TSQ Quantum Ultra, Thermo 
Fisher Scientific). Separation by LC was conducted using NANOSPACE SI-2 (OSAKA 
SODA, Osaka, Japan). Chromatographic separation was performed using a Luna C18 
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100A column (2 × 150 mm, 5.0-μm particle size; Phenomenex, CA, USA) maintained at 
40ºC. The flow rate was 300 μL/min, and the mobile phases were formed using water 
containing 0.1% formic acid as eluent A and acetonitrile containing 0.1% formic acid as 
eluent B. The gradient program was as follows: initial elution with 100% A, followed by 
a linear gradient to 50% B from 3.0 to 4.0 min, to 90% B from 4.0 to 6.0 min, and to 
100% B from 6.0 to 8.0 min, held at 100% B for 12.0 min, and then immediately returned 
to initial conditions and maintained for 3.0 min until the end of the run. LC effluent was 
introduced into the mass spectrometer between 5.0 and 9.0 min after injection. 
Quantitative MS/MS analyses were performed in the selective reaction-monitoring mode. 
Each area under the peak of m/z 330 → 258 (collision energy, 21 V; S-Lens RF amplitude 
voltage, -91 V) for 8-HEZ and of m/z 334 → 258 (collision energy, 23 V; S-Lens RF 
amplitude voltage, -102 V) for 8-HEZ-d4 was measured. The optimized parameters for 
MS were as follows: spray voltage, 2.5 kV; sheath gas pressure, 15 psi; vaporizer 
temperature, 450ºC; capillary temperature, 300ºC; and collision pressure, 1.5 mTorr. The 
sheath gas was nitrogen, and the collision gas was argon. The LC-MS/MS system was 
controlled by Xcalibur software (Thermo Fisher Scientific), which was also used to 
analyze the attained data. The lower limit of 8-HEZ quantification was 5 nM. Standard 
curves for 8-HEZ were constructed in the 0.005–2.5 μM range using authentic metabolite 
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standards. Enzymatic activity was normalized to the amount of CYP2B6 holo-protein 
determined by CO-difference spectra. 
 
2.8. 7-ETC O-deethylation assay 
7-ETC O-deethylation by CYP2B6 was measured as previously reported [22], 
with several modifications. The incubation mixture consisted of the microsomal fraction 
(30 μg), 7-ETC (1.5, 3, 5, 7.5, 12, 20, 30, or 50 μM), 3.3 mM MgCl2, and 100 mM 
potassium phosphate buffer (pH 7.4) in a total volume of 150 μL. Following pre-
incubation at 37ºC for 5 min, reactions were initiated by the addition of NADPH-
generating medium, consisting of 1.3 mM NADP+, 3.3 mM G-6-P, and 0.4 U/mL G-6-
PDH. The mixture was incubated at 37ºC for 20 min. Reactions were terminated by 
adding 150 μL of acetonitrile. 7-ETC O-deethylation determination using 50 μM of 7-
ETC and 30 μg of the microsomal fraction containing wild-type and variant CYP2B6 
showed that 7-HTC formation was linear for incubations of up to 20 min. Moreover, when 
the reaction containing 50 μM of 7-ETC was incubated for 20 min, 7-HTC formation was 
linear in the presence of up to 30 μg of microsomal protein (data not shown). 
After protein removal by centrifugation at 14,000 g for 5 min, 50 μL of the 
supernatant was injected into a high-performance liquid chromatography (HPLC) system 
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consisting of a Nexera series system (SHIMADZU, Kyoto, Japan), a RF10AXL 
fluorescence detector (SHIMADZU), and a YMC-Pack ODS-AQ column (4.6 × 150 mm, 
5-μm particle size; YMC, Kyoto, Japan) maintained at 40ºC. We eluted 7-HTC 
isocratically with 20 mM potassium phosphate buffer (pH 7.4) and methanol (40:60, v/v) 
at a flow rate of 1.0 mL/min. The quantity of 7-HTC was measured at an excitation 
wavelength of 410 nm and emission wavelength of 510 nm. The lower limit of 7-HTC 
quantification was 1 nM. Standard curves for 7-HTC were constructed in the 0.001–1 μM 
range using authentic metabolite. The enzymatic activity was normalized to the amount 
of CYP2B6 holo-protein determined by CO-difference spectra. 
 
2.9. 3D structural modeling of CYP2B6 
The 3D structural modeling of CYP2B6 was based on the CYP2B6 X-ray 
structure reported by Gay et al. (Protein Data Bank code 3IBD) [23]. Because 3IBD 
includes two mutations, Tyr226His and Lys262Arg, these mutants were replaced with 
wild-type residues to construct the CYP2B6.1 model structure. EFZ was docked with the 
CYP2B6.1 model structure according to the CDOCKER protocol of Discovery Studio 
2.5 (BIOVIA, CA, USA). Docking iterations were conducted while considering the 
binding orientation and binding energies in a volume of space defined as nine and the 
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heme iron charge was set to Fe3+. 
 
2.10. Data analysis 
Kinetic data, i.e., Km, Vmax, and CLint (Vmax/Km), were obtained using the Enzyme 
Kinetics Module of SigmaPlot 12.5 (Systat Software, Inc., Chicago, IL, USA), a curve-
fitting program based on nonlinear regression analysis. All values are expressed as the 
mean ± SD of experiments performed in triplicate. Statistical analyses of expression 
levels and kinetic parameters were performed through analysis of variance (one-way 
ANOVA), followed by Dunnett’s T3 test or the Kruskal-Wallis method (IBM SPSS 
Statistics Ver. 22; IBM, Armonk, NY, USA). Differences with P < 0.05 were considered 
statistically significant. 
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3. Results 
3.1. Re-sequencing analysis of SNVs within CYP2B6 exons identified in 1070 Japanese 
To confirm the sequence alterations identified by WGS, we performed Sanger 
sequencing analysis of CYP2B6. For SNVs within exons, the WGS results were the same 
as those obtained from Sanger sequencing. Seven novel CYP2B6 variants were identified 
in 1070 Japanese subjects (Fig. 1). 
 
3.2. Wild-type and variant CYP2B6 expression levels in 293FT cells 
Protein levels of CYP2B6 variants expressed in 293FT cells were assessed by 
western blotting with a polyclonal CYP2B6 antibody that recognized all CYP2B6 
variants tested (Fig. 2). Truncated variants harboring Arg378Ter substitution 
(CYP2B6*28) were stained as intense bands at a lower molecular weight than wild-type 
CYP2B6.1. All of the remaining CYP2B6 variant bands were detected at the correct sizes 
(~ 56 kDa). Expression levels of calnexin, an endoplasmic reticulum-resident protein, 
were virtually constant in microsomes of transfected cells. CYP2B6 protein was not 
detected in cells transfected with empty vector (mock transfection). 
 
3.3. Determination of microsomal CYP2B6 holo-protein contents 
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We measured the reduced CO-difference spectra of the microsomal fractions for 
each CYP2B6 variant. The spectra of all CYP2B6 variants are shown in Fig. 3. We 
detected an increase in the maximum absorption wavelength (λmax) at 450 nm after CO 
treatment for CYP2B6.1 and 28 variants 
(CYP2B6.2–.10, .13, .14, .17, .19, .20, .23, .25–.27, .31–.35, Arg35Cys, Arg145Trp, 
Arg158Gly, Glu339Asp, and Tyr380His). The CYP2B6.1 expression level was 31.5 pmol 
of CYP2B6/mg microsomal protein. Only CYP2B6.19 was expressed at a significantly 
lower level than CYP2B6.1 (11.1 pmol CYP2B6/mg microsomal protein, P < 0.05). The 
expression levels of the remaining 27 variants did not differ significantly from that of 
CYP2B6.1. The expression level of the remaining 11 variants 
(CYP2B6.11, .12, .15, .16, .18, .21, .24, Arg378Ter, .37, Ile382Asn, and Arg443Cys) 
could not be determined because there was no significant increase in their absorption 
maxima at 450 nm (Fig. 4). 
 
3.4. Kinetics of EFZ 8-hydroxylation by CYP2B6 variants 
The kinetic parameters of EFZ 8-hydroxylation were calculated for CYP2B6.1 
and 39 CYP2B6 variants (Table 3). The kinetic parameters for 15 variants 
(CYP2B6.8, .11–.13, .15, .16, .18, .21, .24, Arg378Ter, .35, .37, Arg145Trp, Ile382Asn, 
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and Arg443Cys) could not be determined because the product amounts were below the 
quantification limit at the highest substrate concentration used. CYP2B6.1 Km, Vmax, and 
CLint values were 4.09 μM, 0.35 pmol∙min-1∙pmol-1 CYP2B6, and 0.086 μL∙min-1∙pmol-
1 CYP2B6, respectively. Compared to CYP2B6.1, both CYP2B6.14 and CYP2B6.19 
had significantly higher Km values (P < 0.05), while Tyr380His showed a significantly 
lower Vmax value (P < 0.05), both of which result in reduced CLint values (P < 0.005, P 
< 0.05, and P < 0.005, respectively). CYP2B6.6 had a significantly higher Vmax value (P 
< 0.05), resulting in an increased CLint value (P < 0.005). Additionally, the CLint values 
of CYP2B6.7, 26, .34 (P < 0.05) and .32, .33 (P < 0.005) were significantly higher than 
that of CYP2B6.1. In contrast, the CLint values for CYP2B6.10, Arg158Gly, and 
Glu339Asp (P < 0.05, P < 0.005, and P < 0.01, respectively) were significantly lower 
than that of CYP2B6.1. The kinetic parameters of the remaining CYP2B6 variants were 
not significantly different from that of CYP2B6.1. 
 
3.5. Correlation between the CLint ratios for EFZ 8-hydroxylation and 7-ETC O-
deethylation 
We further calculated the kinetic parameters of 7-ETC O-deethylation for 
CYP2B6.1 and 39 variants. The kinetic parameters of fifteen inactive variants in EFZ 
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metabolism could also not be determined in 7-ETC metabolism because the enzymatic 
activity was not detected at the highest substrate concentration used. The kinetic 
parameters of 7-ETC O-deethylation for CYP2B6.1 and 24 variants were determined 
(Table 4). The CLint values of these variants did not differ significantly from that of 
CYP2B6.1. However, the CLint ratios obtained for 7-ETC O-deethylation were highly 
correlated with EFZ 8-hydroxylation (R2 = 0.837, P < 0.001) (Fig. 5). 
 
3.6. 3D structural modeling analysis 
3D structural modeling was applied to analyze the molecular interactions of 
CYP2B6 variants and EFZ. The Lys139Glu substitution in CYP2B6.8 and .13 was found 
to be disconnected from Pro261 and Thr267 (Fig. 6A). Seven amino acid substitutions 
(Gly99Glu, Ile391Asn, Pro428Thr, Gly476Asn, Ile114Thr, Val183Gly, and Arg443Cys) 
were located near the heme moiety of the CYP2B6 protein. Among them, the Ile114Thr 
substitution in CYP2B6.35 formed hydrophobic interactions with EFZ. Additionally, the 
Gly110Val substitution in CYP2B6.35 formed alkyl interactions with Arg112 and 
Ala116 (Fig. 6B). We further performed 3D structural analysis for the combination of 
Gln172His and Lys262Arg found in various CYP2B6 variants. The Gln172His 
substitution formed various interactions with eight amino acid residues surrounding 
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Thr302 (Fig. 7A). The Lys262Arg substitution formed attractive charge interactions and 
hydrogen bonds with Glu148 and Asp263, respectively (Fig. 7B). 
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4. Discussion 
CYP2B6 is a key drug-metabolizing enzyme and plays an important role in the 
metabolism of clinically relevant drugs. The highly polymorphic nature of CYP2B6 
affects both substrate-dependent and -independent mechanisms of drug metabolism [3]. 
CYP2B6 genetic polymorphisms are associated with large inter-individual responses to 
drug metabolism. In this study, we evaluated the functional changes caused by CYP2B6 
variant alleles by calculating the kinetic parameters of 40 CYP2B6 variant proteins 
expressed in 293FT cells. We determined the kinetic parameters of EFZ 8-hydroxylation 
for CYP2B6.1 and 24 variants. The kinetic parameters of 15 variants could not be 
determined because metabolite amounts were below the quantification limit at the highest 
substrate concentrations assayed. Our study revealed the effects of the allelic 
polymorphisms presented in each variant on enzymatic properties. Because of higher 
correlation between the CLint ratios for EFZ 8-hydroxylation and 7-ETC O-deethylation 
among CYP2B6 variants, functional alterations of CYP2B6 allelic variants gained from 
this study could be applied to various pharmacotherapy for CYP2B6-metabolized drugs. 
Among the 40 CYP2B6 variants, 15 variants were inactive despite confirmation 
of protein expression by western blotting. Eleven of these variants 
(CYP2B6.11, .12, .15, .16, .18, .21, .24, Arg378Ter, .37, Ile382Asn, and Arg443Cys) 
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showed no increase in absorbance at 450 nm after CO-treatment, indicating the absence 
of functional CYP enzymes. Among these, amino acid substitutions in six variants 
(CYP2B6.12, .15, .21, .24, .37, and Arg443Cys) are located near the heme moiety of the 
CYP2B6 protein. Conformational changes near the heme group may affect protein 
function. Met46 is located near a highly conserved proline-rich region, which functions 
as a hinge between the endoplasmic reticulum membrane anchor and the heme-binding 
site [24]. In CYP2B6.11, the conformational alterations caused by the Met46Val 
substitution near the heme-binding site may lead to complete loss of enzymatic activity. 
Ile328Thr, the common amino acid substitution found in CYP2B6.16 and CYP2B6.18, 
is located in the J helix. Although there were no remarkable structural changes regarding 
these substitutions in this study, Kobayashi et al. have suggested that the multiple helices 
present in the structure surrounding the heme group in CYP2B6.18, which differs widely 
from those of CYP2B6.1, promote activity loss [25]. The Arg378Ter substitution, which 
did not show 420 or 450 nm peaks, results in a marked structural change and functional 
inactivity. 
The remaining four inactive variants (CYP2B6.8, .13, .35, and Arg145Trp), 
have detected 450 nm peaks after CO-treatment and for which expression levels have 
been determined, indicating that the observed catalytic activity loss is due to marked 
26 
 
alterations of the crystal structure. Additionally, three of these variants (CYP2B6.13, .35, 
and Arg145Trp) were observed to have a bimodal peak at 420 nm and 450 nm, indicating 
the existence of apo- and holo-protein, respectively. Lys139Glu, the common amino acid 
substitution in both CYP2B6.8 and CYP2B6.13, is located in the C/D loop region and is 
involved in the binding of P450 redox partners [23]. Structurally, position 139, on the 
proximal side of the mammalian CYP2B6 structure, is highly conserved within the 
CYP2 family [26]. Zhang et al. have indicated that cytochrome P450 reductase electron 
transfer is severely impaired in the ferric Lys139Glu variant, resulting in an abolished 
catalytic capacity [27]. In this study, a Lys139 to Glu charge-reversal mutation separates 
from the residues in the G/H loop. This interaction, between the C/D and G/H loops, 
could provide the physical coordination mechanism underlying the observed ligand-
induced conformational changes in the electron-delivery system of this protein [25]. 
Interruption of these interactions within the region may influence enzymatic activity. 
CYP2B6.35, which contains Gly110Val and Ile114Thr substitutions, showed a lack of 
enzymatic activity with both 7-ETC and EFZ. Similarly, Radloff et al. have reported that 
these substitutions result in an almost complete loss of protein function in COS-1 cells 
with respect to bupropion and EFZ [11]. Our results show that the Gly110Val 
substitution forms alkyl interactions with Arg112 and Ala116 located on the C helix, 
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while the Ile114Thr substitution forms hydrophobic interactions with EFZ. All of these 
residues are located in the substrate recognition site (SRS)-1. Therefore, substrate 
interactions caused by conformational changes within SRS-1 may affect the function of 
CYP2B6. 
CYP2B6.1 and all 24 variants with determined kinetic parameters of EFZ 8-
hydroxylation, showed increased absorbance values around 450 nm after CO-treatment. 
Among these, eight variants (CYP2B6.10, .17, .19, .20, .26, .27, .33, and Glu339Asp) 
were observed to have a bimodal peak at 420 nm and 450 nm, indicating the existence 
of apo- and holo-protein, respectively. CYP2B6.14 exhibited a 1.8-fold Km increase, 
resulting in a 22% CLint decrease compared with that of CYP2B6.1. Lang et al. have also 
reported that CYP2B6.14 showed similar activity for bupropion hydroxylation [26]. 
Arg140 is highly conserved within the CYP2 family [26], and the Arg140Gln 
substitution found in CYP2B6.14 is located in the C/D loop. Structural changes in this 
region might affect the affinity of CYP2B6 for EFZ. Additionally, CYP2B6.19 contains 
Gln172His, Lys262Arg, and Arg336Cys substitutions and demonstrated EFZ 
metabolism activity that was 37% of that reported for CYP2B6.1. Moreover, in this study, 
the expression level of the CYP2B6.19 variant was 65% lower than that of CYP2B6.1. 
The Arg336Cys substitution located near the J helix might reduce protein stability, 
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resulting in decreased activity. 
The combination of Gln172His and Lys262Arg are the most common amino 
acid substitutions found amongst CYP2B6 variants. The frequency of the CYP2B6*6 
allele, with these amino acid changes, ranges from 15% to over 60% in various 
populations [3]. In our EFZ 8-hydroxylation analysis, the CYP2B6.6 allele showed a 
significantly increased Vmax (2.8-fold) and CLint value (2.7-fold) compared to that of 
CYP2B6.1. Furthermore, CYP2B6.7, .26, and .34 CLint values were significantly higher 
than those of CYP2B6.1. All of these variants contain Gln172His and Lys262Arg 
substitutions. Jinno et al. have reported that CYP2B6.6 exhibited a 1.9-fold increase than 
that of CYP2B6.1 in its CLint value for 7-ETC metabolism [10]. Radloff et al. have also 
reported that CYP2B6.6 showed a 1.8-fold increase in CLint value while using EFZ as a 
substrate [11]. This increased ratio was similar to that found in our results. Gay et al. 
have reported that Arg262 structurally constitutes part of a small hydrogen-bonding 
network that includes His252, Thr255, and Asp266 [23]. This network of hydrogen 
bonds could influence the orientation of active site residues on the G helix. In our 3D 
structural analysis, the Gln172His substitution forms various interactions with a number 
of residues surrounding Thr302. Thr302 is the covalent modification site of CYP2B6, 
and any structural change in this region may be responsible for enzymatic activity 
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alterations [28]. Additionally, the Lys262Arg substitution interacts with amino acid 
residues in the G/H loop, and conformational changes found between the C/D and G/H 
loops might affect CYP2B6 activity as mentioned above. Our study suggests that 
conformational changes caused by the interaction between the C/D and G/H loops leads 
to increased enzymatic activity and that the overlapping observed between Gln172His 
and Lys262Arg causes structural changes that might enhance metabolic activity. 
However, critical differences have been observed between in vitro and in vivo 
studies, particularly in CYP2B6*6. The mean plasma EFZ concentration in homozygous 
CYP2B6*6 patients infected with HIV was significantly higher than that of patients with 
the heterozygote CYP2B6*6 genotype or those lacking the CYP2B6*6 allele [5, 7]. The 
discrepancy between our results and those identified in clinical research could be caused 
by reduced gene expression and function in the human liver. An investigation using the 
CYP2B6 minigene expression system including intronic regions, the c.516G>T exon 4 
mutation, a nonsynonymous mutation in the CYP2B6*6 allele, was found to be 
responsible for aberrant splicing resulting in a major splice variant that lacks the region 
comprising of exons 4 to 6 [29]. This splicing error causes severely reduced levels of 
mRNA transcript, protein expression, and enzymatic activity, resulting in inter-
individual differences in phenotypic in vivo activity. Given that we use the CYP2B6 
30 
 
cDNA expression system in this study, there is a limit as to what CYP2B6 properties we 
are able to evaluate compared with those assessed using human liver samples. 
We investigated the function of seven novel CYP2B6 variants found in 
Japanese individuals. In our EFZ 8-hydroxylation analysis, Arg35Cys kinetic parameters 
were not significantly different from those of CYP2B6.1. On the other hand, three 
variants (Arg158Gly, Glu339Asp, and Tyr380His located in the D helix, J’ helix, and β2 
strand, respectively) showed significantly lower CLint values than CYP2B6.1. Structural 
changes in these regions might decrease the activity of CYP2B6 for EFZ. Furthermore, 
a different set of three variants (Arg145Trp, Ile382Asn, and Arg443Cys) was inactive. 
Ile382Asn and Arg443Cys did not exhibit peaks at 450 nm, indicating a lack of 
functional proteins. The Ile382 residue interacts with the β1 sheet while Arg443 belongs 
to the L helix. These segments are located near the heme of the CYP2B6 protein, and 
structural changes in these sites result in loss of function. Arg145Trp another inactive 
variant which causes the hydrogen bond between Lys262 and the G/H loop to be severed, 
showed an increase in its absorption maxima at 450 nm. The dissociation of these 
important residues may affect enzymatic activity. As a result, Japanese individuals 
carrying variants, which cause a significant decrease or loss of CYP2B6 activity, are 
expected to be poor metabolizers of their respective substrates. 
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In conclusion, wild-type and 39 CYP2B6 variants were expressed in 293FT 
cells and their enzymatic activities were characterized in vitro. These data revealed the 
functional effects caused by the genetic polymorphisms found in the CYP2B6 allelic 
variants. Comprehensive in vitro assessment of CYP2B6 allelic variants can provide 
novel insight into the allele-specific activity of CYP2B6-metabolized drugs such as EFZ. 
In the future, this approach could lead to the discovery of genotypic-phenotypic 
associations, which can be later used in the development of personalized medicine with 
respect to CYP2B6 genetic polymorphisms. 
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Figure Legends 
Fig. 1. Seven novel CYP2B6 SNVs identified in 1070 Japanese subjects. The shaded box 
numbers correspond to each CYP2B6 exon. The frequencies of the CYP2B6 variants in 
the diagram were observed in 1070 Japanese subjects. 
 
Fig. 2. Western blots showing immunoreactive CYP2B6 proteins (upper panel) and 
calnexin (lower panel). Western blotting was performed according to standard procedures 
using SDS-PAGE. Five micrograms of microsomal fractions, containing CYP2B6 variant 
proteins, were loaded onto each lane. CYP2B6 variants and calnexin were detected using 
polyclonal antibodies against the respective proteins. The numbers correspond to each 
CYP2B6 variant. 
 
Fig. 3. Representative CO difference spectra of CYP2B6 variant proteins expressed in 
293FT cells. 
 
Fig. 4. Expression levels of CYP2B6 proteins expressed in 293FT cells. Each bar is 
presented as the mean ± S.D. of three independently performed CO-difference spectra 
readings. The numbers correspond to each CYP2B6 variant. 
41 
 
*P < 0.05 compared to CYP2B6.1. 
 
Fig. 5. Correlation between the CLint ratios (relative to CYP2B6.1) for EFZ 8-
hydroxylation and 7-ETC O-deethylation among CYP2B6 variants. EFZ 8-hydroxylation 
CLint ratios are plotted on the horizontal axis and 7-ETC O-deethylation CLint ratios are 
plotted on the vertical axis. Numbers correspond to CYP2B6 variants. Each bar is 
presented as the mean ± S.D. of three independently performed catalytic assays. The 
correlation was analyzed using a weighted linear regression analysis using IBM SPSS 
Statistics. 
 
Fig. 6. Diagram showing part of the crystal structures of CYP2B6.1 (left panel) and 
CYP2B6 variants (right panel). The Lys139 and Glu139 residues in CYP2B6.1 are shown 
in yellow (A). The Gln110 and Ile114 residues in CYP2B6.1, as well as the Val110 and 
Thr114 residues in CYP2B6.35, are shown in yellow (B). Hydrogen bonds, attractive 
charge interactions, alkyl interactions, and pi-anion interaction are shown in light green, 
red, purple, and mustard lines respectively. 
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Fig. 7. Diagram showing part of the crystal structures of CYP2B6.1 (left panel) and 
CYP2B6 variants (right panel). The CYP2B6.1 Gln172 residue and the CYP2B6 His172 
variant residue are shown in yellow. The Thr302 residue is shown in green. The amino 
acid residues forming interactions with either Gln172 or His172 are included in diagram 
(A). The CYP2B6.1 residue Lys262 and the CYP2B6 variants residue Arg262 are both 
shown in yellow. Hydrogen bonds and attractive charge interactions are shown with a 
light green and red line, respectively (B). 
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Table 1 CYP2B6 allelic variants characterized in this study. 
Variants Protein Nucleotide changes Amino acid changes 
CYP2B6*1 CYP2B6.1   
CYP2B6*2 CYP2B6.2 64C>T Arg22Cys 
CYP2B6*3 CYP2B6.3 777C>A Ser259Arg 
CYP2B6*4 CYP2B6.4 785A>G Lys262Arg 
CYP2B6*5 CYP2B6.5 1459C>T Arg487Cys 
CYP2B6*6 CYP2B6.6 516G>T; 785A>G Gln172His; Lys262Arg 
CYP2B6*7 CYP2B6.7 516G>T; 785A>G; 1459C>T Gln172His; Lys262Arg; Arg487Cys 
CYP2B6*8 CYP2B6.8 415A>G Lys139Gln 
CYP2B6*9 CYP2B6.9 516G>T Gln172His 
CYP2B6*10 CYP2B6.10 62A>T; 64C>T; 216G>T Gln21Leu; Arg22Cys 
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CYP2B6*11 CYP2B6.11 136A>G Met46Val 
CYP2B6*12 CYP2B6.12 296G>A Gly99Glu 
CYP2B6*13 CYP2B6.13 415A>G; 516G>T; 785A>G Lys139Gln; Gln172His; Lys262Arg 
CYP2B6*14 CYP2B6.14 419G>A Arg140Gln 
CYP2B6*15 CYP2B6.15 1172T>A Ile391Asn 
CYP2B6*16 CYP2B6.16 785A>G; 983T>C Lys262Arg; Ile328Thr 
CYP2B6*17 CYP2B6.17 76A>T; 83A>G; 85T>A; 86G>C Thr26Ser; Asp28Gly; Arg29Thr 
CYP2B6*18 CYP2B6.18 983T>C Ile328Thr 
CYP2B6*19 CYP2B6.19 516G>T; 785A>G; 1006C>T Gln172His; Lys262Arg; Arg336Cys 
CYP2B6*20 CYP2B6.20 503C>T; 516G>T; 785A>G Thr168Ile; Gln172His; Lys262Arg 
CYP2B6*21 CYP2B6.21 1282C>A Pro428Thr 
CYP2B6*23 CYP2B6.23 1375A>G Met459Val 
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CYP2B6*24 CYP2B6.24 1427G>A Gly476Asp 
CYP2B6*25 CYP2B6.25 1454A>T Gln485Leu 
CYP2B6*26 CYP2B6.26 499C>G; 516G>T; 785A>G Pro167Ala; Gln172His; Lys262Arg 
CYP2B6*27 CYP2B6.27 593T>C Met198Thr 
CYP2B6*28  (917C>G); 1132C>T (Thr306Ser); Arg378Ter 
CYP2B6*31 CYP2B6.31 937C>A Leu313Ile 
CYP2B6*32 CYP2B6.32 1219G>A Ala407Thr 
CYP2B6*33 CYP2B6.33 1459C>A Arg487Ser 
CYP2B6*34 CYP2B6.34 516G>T; 785A>G; 1459C>A Gln172His; Lys262Arg; Arg487Ser 
CYP2B6*35 CYP2B6.35 329G>T; 341T>C; 444G>T;  
593T>C; 835G>C 
Gln110Val; Ile114Thr; Glu148Asp;  
Met198Thr; Ala279Pro 
CYP2B6*37 CYP2B6.37 516G>T; 548T>G; 785A>G Gln172His; Val183Gly; Lys262Arg 
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Novel variant 1  103C>T Arg35Cys 
Novel variant 2  433C>T Arg145Trp 
Novel variant 3  472C>G Arg158Gly 
Novel variant 4  1017G>C Glu339Asp 
Novel variant 5  1138T>C Tyr380His 
Novel variant 6  1145T>A Ile382Asn 
Novel variant 7  1327C>T Arg443Cys 
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Table 2 PCR primers used to amplify sequences of the human CYP2B6 gene to confirm the novel allelic variants observed in 1070 Japanese subjects. 
Nucleotide change 
Primer (5′ –3′) 
Product length (bp) 
Forward Reverse 
103C>T GTGCAGGGCAGTCAGACCAG CAAGGCAAGAAGCAGCTCAC 243 
433C>T 
472C>G 
CAGGTGTGATCTTTGCCAATG GATGGTGTCTCCAGTTTCGTC 280 
1017G>C 
1138T>C 
1145T>A 
CCACCTCAACCTCCAAAATTG GATATTGCCATTCCCTCCAAC 454 
1327C>T GCAGTGGACATTTGTGTCTGG CTCACTTGCAATGTGACCTCAG 441 
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Table 3 Kinetic parameters of EFZ 8-hydroxylation 
Variants 
Km  
(μM) 
Vmax  
(pmol/min/pmol CYP2B6) 
CLint (Vmax/Km) 
(μL/min/pmol CYP2B6) 
% of wild-type CLint 
CYP2B6.1 4.09 ± 0.15 0.35 ± 0.03 0.086 ± 0.004  
CYP2B6.2 4.53 ± 0.42 0.37 ± 0.02 0.081 ± 0.003 95% 
CYP2B6.3 4.57 ± 1.22 0.28 ± 0.02 0.064 ± 0.013 75% 
CYP2B6.4 3.70 ± 0.66 0.38 ± 0.00 0.105 ± 0.020 122% 
CYP2B6.5 4.13 ± 0.44 0.38 ± 0.06 0.094 ± 0.018 109% 
CYP2B6.6 4.34 ± 0.20 0.99 ± 0.06* 0.228 ± 0.006*** 266% 
CYP2B6.7 4.82 ± 0.22 0.69 ± 0.05 0.143 ± 0.007* 166% 
CYP2B6.8 N.D. N.D. N.D.  
CYP2B6.9 5.31 ± 0.27 0.78 ± 0.04 0.148 ± 0.016 172% 
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CYP2B6.10 6.04 ± 1.13 0.26 ± 0.03 0.044 ± 0.005* 51% 
CYP2B6.11 N.D. N.D. N.D.  
CYP2B6.12 N.D. N.D. N.D.  
CYP2B6.13 N.D. N.D. N.D.  
CYP2B6.14 7.27 ± 1.95* 0.13 ± 0.01 0.019 ± 0.004*** 22% 
CYP2B6.15 N.D. N.D. N.D.  
CYP2B6.16 N.D. N.D. N.D.  
CYP2B6.17 4.11 ± 0.42 0.30 ± 0.00 0.073 ± 0.007 85% 
CYP2B6.18 N.D. N.D. N.D.  
CYP2B6.19 7.09 ± 1.13* 0.22 ± 0.01 0.032 ± 0.006* 37% 
CYP2B6.20 1.51 ± 0.58 0.41 ± 0.03 0.311 ± 0.139 363% 
CYP2B6.21 N.D. N.D. N.D.  
50 
 
CYP2B6.23 3.74 ± 0.24 0.38 ± 0.02 0.103 ± 0.007 120% 
CYP2B6.24 N.D. N.D. N.D.  
CYP2B6.25 2.85 ± 0.66 0.20 ± 0.01 0.072 ± 0.013 85% 
CYP2B6.26 2.74 ± 0.16 0.43 ± 0.01 0.157 ± 0.011* 183% 
CYP2B6.27 1.73 ± 0.46 0.11 ± 0.01 0.067 ± 0.015 79% 
Arg378Ter N.D. N.D. N.D.  
CYP2B6.31 5.35 ± 0.87 0.63 ± 0.07 0.118 ± 0.006 137% 
CYP2B6.32 3.63 ± 0.20 0.56 ± 0.01 0.153 ± 0.005*** 179% 
CYP2B6.33 4.81 ± 0.46 0.68 ± 0.05 0.142 ± 0.004*** 165% 
CYP2B6.34 4.85 ± 0.59 0.71 ± 0.04 0.147 ± 0.009* 171% 
CYP2B6.35 N.D. N.D. N.D.  
CYP2B6.37 N.D. N.D. N.D.  
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Arg35Cys 3.77 ± 0.54 0.23 ± 0.02 0.062 ± 0.011 73% 
Arg145Trp N.D. N.D. N.D.  
Arg158Gly 5.95 ± 1.75 0.15 ± 0.02 0.026 ± 0.005*** 30% 
Glu339Asp 4.05 ± 0.17 0.20 ± 0.00 0.049 ± 0.002** 57% 
Tyr380His 5.52 ± 0.89 0.10 ± 0.01* 0.019 ± 0.002*** 22% 
Ile382Asn N.D. N.D. N.D.  
Arg443Cys N.D. N.D. N.D.  
These data represent the mean ± SD of three independently performed catalytic assays. 
*P < 0.05, **P < 0.01, and ***P < 0.005 compared with CYP2B6.1. N.D. represents not determined. 
The kinetic parameters of EFZ 8-hydroxylation regarding 15 variants could not be determined because the enzymatic activity of CYP2B6 was not 
detected at the highest substrate concentration assayed (20 μM EFZ). 
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Table 4 Kinetic parameters of 7-ETC O-deethylation 
Variants 
Km  
(μM) 
Vmax  
(pmol/min/pmol CYP2B6) 
CLint (Vmax/Km) 
(μL/min/pmol CYP2B6) 
% of wild-type CLint 
CYP2B6.1  7.58 ± 1.50 2.11 ± 0.44 0.279 ± 0.005  
CYP2B6.2 14.90 ± 3.84 2.85 ± 0.82 0.190 ± 0.010 68% 
CYP2B6.3 19.07 ± 7.54 1.36 ± 0.07 0.082 ± 0.042 30% 
CYP2B6.4  5.80 ± 0.84 2.61 ± 0.33 0.451 ± 0.031 162% 
CYP2B6.5  7.65 ± 1.20 2.88 ± 0.19 0.380 ± 0.038 137% 
CYP2B6.6  7.85 ± 0.71 3.53 ± 0.24 0.453 ± 0.054 163% 
CYP2B6.7 16.22 ± 3.39 6.73 ± 1.10* 0.419 ± 0.040 150% 
CYP2B6.9 14.24 ± 3.03 3.56 ± 0.33 0.255 ± 0.040 92% 
CYP2B6.10 15.78 ± 0.17 1.60 ± 0.38 0.101 ± 0.025 36% 
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CYP2B6.14 24.34 ± 3.64 1.09 ± 0.12 0.045 ± 0.004 16% 
CYP2B6.17 24.92 ± 4.36 0.85 ± 0.06 0.035 ± 0.003 12% 
CYP2B6.19 45.34 ± 10.94 1.59 ± 0.60 0.034 ± 0.006 12% 
CYP2B6.20  8.55 ± 2.12 4.70 ± 0.24* 0.571 ± 0.132 205% 
CYP2B6.23  6.79 ± 1.44 3.17 ± 0.26 0.476 ± 0.067 171% 
CYP2B6.25 13.83 ± 2.06 2.62 ± 0.07 0.192 ± 0.023 69% 
CYP2B6.26  9.10 ± 2.46 4.11 ± 0.57 0.464 ± 0.070 167% 
CYP2B6.27  3.30 ± 0.42 1.24 ± 0.03 0.378 ± 0.044 136% 
CYP2B6.31  6.62 ± 1.34 2.94 ± 0.20 0.454 ± 0.077 163% 
CYP2B6.32  5.57 ± 0.10 3.27 ± 0.13 0.587 ± 0.033 211% 
CYP2B6.33  7.96 ± 3.24 3.33 ± 0.58 0.472 ± 0.204 169% 
CYP2B6.34 12.14 ± 1.61 5.53 ± 0.21* 0.460 ± 0.043 165% 
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Arg35Cys 10.28 ± 1.03 2.37 ± 0.13 0.232 ± 0.012 83% 
Arg158Gly 15.18 ± 2.51 1.59 ± 0.04 0.106 ± 0.016 38% 
Glu339Asp 26.34 ± 6.16 2.12 ± 0.11 0.084 ± 0.022 30% 
Tyr380His 28.67 ± 1.29*** 1.14 ± 0.09 0.040 ± 0.004 14% 
These data represent the mean ± SD of three independently performed catalytic assays. 
*P < 0.05, and ***P < 0.005 compared with CYP2B6.1. 
The kinetic parameters of 7-ETC O-deethylation regarding 15 variants (CYP2B6.8, .11–.13, .15, .16, .18, .21, .24, Arg378Ter, .35, .37, Arg145Trp, 
Ile382Asn, and Arg443Cys) could not be determined because the enzymatic activity of CYP2B6 was not detected at the highest substrate concentration 
assayed (50 μM 7-ETC). 
 
